Most identified that CD4 counts were used to assess antiretroviral (ARV) therapy eligibility among HIV patients (38/40; 95%) and knew that isoniazid preventive therapy was used to prevent tuberculosis (36/40; 90%). The gene discussed is CD4; the disease is tuberculosis.